METHODS: In this randomised, single-blind, placebo-controlled study, 42 patients with Type 2 DM were randomly allocated to receive either P. atlantica oleoresin or placebo capsule for 3 months. Patients were evaluated prior to and 12 weeks after the beginning of the intervention, in terms of changes in lipid profiles, glucose indices and BP.
RESULTS: After 3 months, the mean BP in patients with DM receiving P. atlantica oleoresin was significantly reduced compared with the baseline (p = 0.001). Also, these changes were significantly higher than those of the control group. The mean of total cholesterol (p = 0.89), low-density lipoprotein (LDL) (p = 0.43) and triglyceride (TG) (p = 0.98) in the intervention group after 3 months was lower than that in the control group, but this difference was not statistically significant.
CONCLUSIONS: After 3 months, there was no significant difference between the P. atlantica and control groups in terms of blood sugar and lipid profiles. The mean BP in patients with DM receiving P. atlantica oleoresin was significantly reduced compared with that in the beginning of the study. Also, these changes were significant compared with the control group.
方法:在这个随机的,单盲,安慰剂对照研究,42名2型DM患者随机分配接受3个月的Atlantica油树脂或安慰剂胶囊。在开始干预之前和之后12周对患者进行评估,就脂质分布的变化而言,血糖指数和血压。
结果:3个月后,与基线相比,接受Atlandica油树脂治疗的DM患者的平均BP显著降低(p=0.001).此外,这些变化明显高于对照组.总胆固醇的平均值(p=0.89),3个月后干预组低密度脂蛋白(LDL)(p=0.43)和甘油三酯(TG)(p=0.98)低于对照组,但这种差异没有统计学意义。
结论:3个月后,在血糖和血脂谱方面,阿本菌与对照组之间没有显着差异。与研究开始时相比,接受Atlantica油树脂的DM患者的平均BP显着降低。此外,与对照组相比,这些变化显著。